Browse > Article

Anti-cancer Effect of Hematopoietic Stem Cell-derived Allogeneic-DC Vaccine in Melanoma Metastasis Model  

Kim, Myoung-Joo (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Shon, Hye-Jin (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Baek, So-Young (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Kang-Eun (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Young-Joon (Medipost Biomedical Research Institute)
Lee, Hyun-Ah (The Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
IMMUNE NETWORK / v.6, no.3, 2006 , pp. 154-162 More about this Journal
Abstract
Background: Dendritic cell (DC)-based cancer immunotherapy is studied for several years. However, it is mainly derived from autologous PBMC or leukapheresis from patient, which has limitations about yield and ability of DC production according to individual status. In order to solve these problems, inquiries about allogeneic DCs are performed but there are no preclinical trial answers for effect or toxicity of allogeneic DC to use for clinical trial. In this study, we compared the anti-tumor effect of allogeneic and autologous DCs from mouse bone marrow stem cells in mouse metastatic melanoma model. Methods: B16F10 melanoma cells ($5{\times}10^4$/mouse) were injected intravenously into the C57BL/6 mouse. Therapeutic DCs were differentiated from autologous (C57BL/6: CDC) or allogeneic (B6C3F1: BDC) bone marrow stem cells with GM-CSF, SCF and IL-4 for 13days and pulsed with B16F10 tumor cell lysate (Blys) for 18hrs. DC intra-peritoneal injections began on the 8th day after the tumor cell injection by twice with one week interval. Results: Anti-tumor response was observed by DC treatment without any toxicity especially in allogeneic DC treated mice (tumor burden score: $2.667{\pm}0.184,\;2.500{\pm}0.463,\;2.000{\pm}0.286,\;1.500{\pm}0.286,\;1.667 {\pm}0.297$ for saline, CDC/unpulsed-DC: U-DC, CDC/Blys-DC, BDC/U-DC and BDC/Blys-DC, respectively). IFN-${\gamma}$ secretion was significantly increased in allogeneic DC group stimulated with B16F10 cell lysate ($2,643.3{\pm}5,89.7,\;8,561.5{\pm}2,204.9.\;6,901.2{\pm}141.1pg/1{\times}10^6$ cells for saline, BDC/U-DC and BDC/Blys-DC, respectively) with increased NK cell activity. Conclusion: Conclusively, promising data was obtained that allogeneic DC can be used for DC-based cancer immunotherapy.
Keywords
Stem cell-derived DC; allogeneic DC; anti-cancer immunotherapy;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Lee YJ, Kim MJ, IN SH, Choi OM, Baek S, Kwon YD, Lee H: Effect of dendritic cell based cancer vaccine using allogeneic tumor cell lysate in melanoma pulmonary metastasis model. Immune Network 5;163-171, 2005   과학기술학회마을   DOI
2 Lee H, Choi KM, Baek S, Lee HG, Jung CW: Dendritic cell based cancer immunotherapy: in vivo study with mouse renal cell carcinoma model. Immune Network 4;44-52, 2004   DOI
3 Li-Cheng Xu RL, Tang Y, Ogburn PL Malinowski K, Malhjewicz S, Santiago-Schwarz F, Fan Q: Implication of delayed TNF-alpha exposure on dendritic cell maturation and expansion from cryopreserved cord blood CD3$4^{+}$ hematopoietic progenitors. J Immunol Methods 293;169-182, 2004   DOI   ScienceOn
4 Guanghua G, Suzuan C, Juan Z, Lili I., Jing Y, Hongmei D, Hong X, Zhongjing S, Libiao W: Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine 23;5225-5230, 2005   DOI   ScienceOn
5 Yoon HL Singh K, Ratner S, Reiners JJ: Phorbol ester effects on splenic lymphocyte composition and cytotoxic T cell activities of SSIN mice: a strain deficient in CD$8^{+}$ T cells. Carcinogenesis 17;2617-2624, 1996   DOI   ScienceOn
6 Pulendran B, Maraskovsky E, Banchereau J, Malaliszewski C: Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22;41-47, 2001   DOI   ScienceOn
7 Martin P, Martinez del Hoyo G, Anjuere F, Ruiz SR, Arias CF, Marin AR, Ardavin C: Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8$alpha^{-}$ and CD8 $ alpha^{+}$ dendritic cells are generated from CD lymphoidcommitted precursors. Blood 96;2511-2519, 2000
8 O'Garra A, Vieira P: Regulatory T cells and mechanisms of immune system control. Nat Med 10;801-805, 2004   DOI   ScienceOn
9 Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB: Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42;535-539, 2005   DOI   ScienceOn
10 Marten A, Renoth S, Heinicke T, Alebers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Ruecker A V, EisHubinger AM, Muller S, Schwaner I, Lohmann U, Heymann G, Sauerbruch T, Scgmidt-Wolf IGH: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/ll trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14;483-494, 2003   DOI   ScienceOn
11 Figdor CG, De Vires IJM, Lesterhuis WJ, Melief CJM: Dendritic cell immunotherapy: mapping the way. Leuk Lymphoma 10;475-480, 2004
12 Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Santinami M: Immnotherapy of melanoma. Sernin Cancer Biol 13;391-400, 2003   DOI   ScienceOn
13 Moser M, Murphy KM: Dendritic cell regulation of T$T_{H}1-T_{H}$2 development. Nature Immunol 1;199-204, 2000   DOI   ScienceOn
14 Van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA: Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 171;5842-5852, 2003   DOI
15 Curti A, Isioiri A, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli Rvl: Generation of dendritic cells from positively selected CD1$ 4^{+}$ monocytes for antitumor immunotherapy. Leukemia & Lymphoma 45;1419-1428, 2004   DOI   ScienceOn
16 Encabo A, Solves P, Mateu E, Sepulveda P, Carbonell-Uberos F, Minana MD: Selective generation of different dendritic cell precursors from CD3$ 4^{+}$ cells by intcrlcukin-6 and interleukin-3. Stem Cells 22;725-740, 2004   DOI   ScienceOn
17 Lee SJ, Kim MJ, In SH, Baek S, Lee H: Immunocell therapy for lung cancer: dendritic cell based adjuvant therapy in mouse lung cancer model. Immune Network 5;36-44, 2005   과학기술학회마을   DOI
18 Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA: NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 55; 1122-1131, 2006   DOI
19 Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Penelope AM, Storkus WJ, Kalinski P: Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 171;2366-2373, 2003   DOI
20 Dilioglou S, Cruse JM, Lewis RE: Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp Mol Pathol 75;217-227, 2003   DOI   ScienceOn
21 Wagner JE, Barker JN, Defor TE, Baker KC, Blazer BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NKC, Davies SM: Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100;1611-1618, 2002
22 Nencioni A, Brossart P: Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 22;501-513, 2004   DOI   ScienceOn
23 Holtl L, Zeller-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL Coggin JH Jr, Thurnher M: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8;3369-3376, 2002
24 Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Pavolovic SV: Clinical-grade manufacturing of DC from CD1$ 4^{+}$ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 6;563-570, 2004   DOI   ScienceOn
25 Mohty M, Olive D, Gaugler B: Leukemic dendritic cells: Potential for therapy and insights towards immune escape by leukemic blasts. Leukemia 16;2197-2204, 2002   DOI   ScienceOn
26 Ward KA, Stewart LA, Schwarer AP: CD34$^{+}$ -derived CD11c $^{+++}$ BDCA-1 $^{++}$ CD123$^{++}$ DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy 8;130-140, 2006   DOI   ScienceOn
27 O'Rourke MGE, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KAO, Schmidt CW: Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/ dendritic cell vaccine. Cancer Immunol Immunother 52;387-395, 2003
28 Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Cehn CL, Kawano K, Kitano S: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52;155-161, 2003
29 Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszynska A, Schmitt M: Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19;1621-1627, 2005   DOI   ScienceOn
30 Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Toerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195;1279-1288, 2002   DOI
31 Guardino AE, Rajapaksa R, Ong KH, Sheehan K, Levy R: Production of myeloid dendritic cells (DC) pulsed with tumorspecific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy 8;277-289, 2006   DOI   ScienceOn
32 Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, Munz C, Heller G, Young JW: Mature human langerhans cells derived from CD3$4^{+}$ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactivc IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocytederived dendritic cells. J Immunol 173;2780-2791, 2004   DOI
33 Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchicri G: The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174;727-734, 2005   DOI
34 Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taicli B: Vaccination of patients with B-cell lymphoma using autol ogous antigen-pulsed dendritic cells. Nat Med 2;52-58, 1996   DOI   ScienceOn